论文部分内容阅读
目的:探讨自体树突状细胞-细胞因子诱导的杀伤细胞(DC-CIK)联合常规化疗治疗转移性胰腺癌患者的近、远期效果。方法:选取96例转移性胰腺癌患者随机分为对照组与观察组,每组各48例,对照组患者行单纯替吉奥化疗,观察组在替吉奥化疗的基础上联合使用自体DC-CIK治疗,比较两组的近期(两个疗程后)疗效与远期预后。结果:对照组与观察组的缓解率差异无统计学意义(39.58%vs.27.08%,P>0.05),但总有效率明显升高(77.08%vs.58.33%,P<0.05);两组治疗前T淋巴细胞亚群、IFN-γ与IL-4水平差异均无统计学意义(均P>0.05),治疗后,观察组CD3~+细胞、CD4~+细胞、CD4~+/CD8~+比值、IFN-γ水平明显高于对照组(P<0.05),CD8~+细胞、IL-4水平明显低于对照组(P<0.05)。两组患者的治疗过程中各毒副反应的发生率无明显差异(均P>0.05)。观察组患者平均生存期与1、2、3年生存率均明显高于对照组(15.0个月vs.10.0个月;66.67%、29.17%、8.33%vs.43.75%、10.42%、0,均P<0.05)。结论:自体DC-CIK联合常规化疗对转移性胰腺癌患者近期疗效、远期预后均具有改善作用。
Objective: To investigate the short-term and long-term effects of autologous dendritic cells-cytokine-induced killer cells (DC-CIK) combined with conventional chemotherapy in patients with metastatic pancreatic cancer. Methods: Ninety-six patients with metastatic pancreatic cancer were randomly divided into control group and observation group, with 48 patients in each group. Patients in the control group were treated with turegine alone. The observation group was treated with autologous DC- CIK treatment, the two groups of recent (after two courses of treatment) and long-term prognosis. Results: There was no significant difference in response rate between the control group and the observation group (39.58% vs.27.08%, P> 0.05), but the total effective rate was significantly increased (77.08% vs.58.33%, P <0.05) There was no significant difference in the level of T-lymphocyte subsets, IFN-γand IL-4 before treatment (all P> 0.05). After treatment, CD3 ~ + cells, CD4 ~ + cells, CD4 ~ + / CD8 ~ (P <0.05). The levels of CD8 + cells and IL-4 were significantly lower than those of the control group (P <0.05). There was no significant difference in the incidence of side effects between the two groups (all P> 0.05). The average survival time of patients in the observation group and the survival rates at 1, 2 and 3 years were significantly higher than those in the control group (15.0 months vs. 10.0 months; 66.67%, 29.17%, 8.33% vs.43.75%, 10.42%, 0 P <0.05). Conclusion: The combination of autologous DC-CIK and conventional chemotherapy can improve the short-term curative effect and long-term prognosis of patients with metastatic pancreatic cancer.